RT期刊文章老电子T1最小平均临床重要差异,最好,最坏,电流强度和不愉快的慢性呼吸困难摩根富林明欧洲呼吸杂志乔和J FD欧元欧洲呼吸学会SP 1902202 10.1183/13993003.02202 -2019 A1马格努斯埃克斯特龙A1米利暗黄J·约翰逊A1曹国伟A1 David c .克鲁年2020 UL //www.qdcxjkg.com/content/early/2020/04/20/13993003.188bet官网地址02202 AB - 2019. -抽象背景慢性呼吸困难造成了灾难性的后果。最小临床重要的区别(MCID)电流强度被估计为9毫米100毫米视觉模拟量表(血管)。我们旨在确定MCIDs常用的维度和召回时间:当前的不愉快和电流、平均水平,最好和最差的最后24小时强度慢性呼吸困难。方法这是一个二次分析的随机对照试验吗啡和安慰剂在患有慢性呼吸困难7天从严重的疾病。呼吸困难分数自述使用日记每天晚上在100 mm血管。每个分数估计的改进MCID使用基于锚和分配方法。结果283名参与者(平均年龄74.2岁;男性63%;58%的慢性阻塞性肺病;湄公河委员会3 - 4 87.0%)被包括在内。Anchor-based MCIDs气喘吁吁的分数范围从−−9.5毫米13.9毫米。MCIDs正相似时,使用不同的主持人和所有参与者,参与者和更严重的呼吸困难(湄公河委员会3 - 4),分别。 Distribution based effect sizes were: small (−4.7 to −6.3 mm), moderate (−9.4 to −12.5 mm) and large effect (−15.0 to −20.0 mm). Sample sizes for trials using the different scores were proposed. MCIDs of absolute change were more stable than using relative change from baseline.Conclusion An improvement of about 10 mm on a 100 mm VAS is likely to be clinically meaningful across commonly used measures of chronic breathlessness (current intensity, unpleasantness, and average, best and worst intensity over the last 24 h) – to evaluate clinical benefit and effects in therapeutic trials.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Ekström has nothing to disclose.Conflict of interest: Dr. Johnson has nothing to disclose.Conflict of interest: Dr. Huang has nothing to disclose.Conflict of interest: Dr. Currow reports and is an unpaid member of an advisory board for Helsinn Pharmaceuticals, is a consultant to Specialised Therapeutics and Mayne Pharma and received intellectual property payments from Mayne Pharma.